WO2021249760A1 - Composition cosmétique comprenant du 6-méthyl-picolinamide - Google Patents

Composition cosmétique comprenant du 6-méthyl-picolinamide Download PDF

Info

Publication number
WO2021249760A1
WO2021249760A1 PCT/EP2021/063837 EP2021063837W WO2021249760A1 WO 2021249760 A1 WO2021249760 A1 WO 2021249760A1 EP 2021063837 W EP2021063837 W EP 2021063837W WO 2021249760 A1 WO2021249760 A1 WO 2021249760A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
skin
resorcinol
picolinamide
acid
Prior art date
Application number
PCT/EP2021/063837
Other languages
English (en)
Inventor
Rezwan Shariff
Anita DAMODARAN
Original Assignee
Unilever Ip Holdings B.V.
Unilever Global Ip Limited
Conopco, Inc., D/B/A Unilever
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unilever Ip Holdings B.V., Unilever Global Ip Limited, Conopco, Inc., D/B/A Unilever filed Critical Unilever Ip Holdings B.V.
Publication of WO2021249760A1 publication Critical patent/WO2021249760A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/347—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations

Definitions

  • the present invention relates to a cosmetic composition.
  • the present invention relates to a cosmetic composition that provides even tone to skin together with skin brightening.
  • Skin is the outermost protective covering of living beings; and is the largest organ in the body. It acts as a barrier and protects the body from external factors e.g. dust, dirt, pollution and ultraviolet radiation contained in sunlight. Skin also helps prevent entry of harmful or potentially harmful microbes e.g. bacteria, fungi and viruses, from entering the body thereby preventing infection and/or other ill effects that may be caused.
  • skin is always exposed to one or more factors mentioned earlier.
  • skin is susceptible to developing one or more conditions e.g. dryness, wrinkles, loose/saggy skin, age spots, blotchy skin, melasma, freckle and increased pigmentation, which may lead to less preferred uneven skin tone.
  • One of the ways to reduce occurrence of such conditions is to avoid exposure to factors causing such conditions.
  • factors causing such conditions are difficult, and at times, unavoidable.
  • cosmetic compositions comprising one or more actives that deliver benefits e.g. moisturizing, anti-aging and skin brightening, when applied on a surface of the human body e.g. skin.
  • WO 2017/215863 A1 discloses a cosmetic composition comprising: (i) at least one pyridine compound of Formula I or II disclosed therein (ii) an alkyl substituted resorcinol; and, (iii) a dermatologically acceptable base. Also disclosed is use of a pyridine compound of Formula I or II disclosed therein in the preparation of a cosmetic composition which provides enhanced TDD of an alkyl substituted resorcinol.
  • WO 2017/215863 A1 discloses a combination of picolinamide and 4-hexyl resorcinol.
  • WO2013/030794 A2 discloses a skin depigmentation composition containing picolinamide or isonicotinamide and said composition further comprises 4- substituted resorcinol.
  • Need therefore exists to provide a cosmetic composition comprising new actives that provide benefits e.g. even skin tone.
  • 6-methyl picolinamide (6-MP) provides superior even skin tone and brightening as compared to that provided by known skin lightening actives e.g. kojic acid. Further, it has also been found that 6-MP when combined with a known skin lightening active e.g. 4-hexyl resorcinol (4-HR), provides synergistic reduction in melanin content that gives the consumer a more even skin tone that also appears bright and glowing.
  • the present invention relates to a cosmetic composition comprising from 0.001 to 10 wt% 6-methyl picolinamide.
  • the present invention relates to a method for providing even tone to skin wherein the method comprises:
  • the present invention relates to the use of the composition of the first aspect for providing even tone to skin.
  • the present invention relates to the use of 6-methyl picolinamide for providing even tone to skin.
  • “Skin” as used herein is meant to include skin on the face and body (e.g., neck, chest, back, arms, underarms, hands, legs, buttocks and scalp).
  • the composition as per the present invention is preferably but especially useful for application to skin areas with the highest incidence of hyperpigmentation such as-face and underarms, most preferably the composition is a skin cosmetic composition, e.g., creams, deodorants and anti-perspirants.
  • “Even toned skin” as used herein, preferably means the evening out the spots
  • a cosmetic composition according to the present invention (the composition) relates to a cosmetic composition comprising from 0.001 to 10 wt% 6-MP. 6-MP
  • composition comprises 6-MP, also known as 2-pyridinecarboxamide, 6-methyl- (CAS number: 63668-37-1); that has the following structure:
  • the composition comprises from 0.001 to 10 wt%, preferably from 0.01 to 9 wt%, more preferably from 0.1 to 7 wt%, even more preferably from 0.1 to 5 wt%, further more preferably from 0.1 to 3 wt%, still more preferably from 0.1 to 2 wt%, yet more preferably from 0.1 to 1 wt% 6-MP.
  • 6-MP is not encapsulated.
  • 6-MP provides the desired even skin tone. Moreover, it has been found that such effect obtained is superior than that obtained using a known agent e.g. kojic acid. Additional skin lightening agent
  • the composition further comprises one or more additional skin lightening agents.
  • additional skin lightening agents include niacinamide, picolinamide, 4-alkyl substituted resorcinol, vitamin B6, vitamin C, vitamin A, glutathione precursors, galardin, adapalene, aloe extract, ammonium lactate, arbutin, azelaic acid, butyl hydroxy anisole, butyl hydroxy toluene, citrate esters, deoxyarbutin, 1,3-diphenyl propane derivatives, 2,5-dihydroxybenzoic acid and its derivatives, 2-(4- acetoxyphenyl)-1,3-dithiane, 2-(4-hydroxyphenyl)-1,3-dithiane, ellagic acid, gluco pyranosyl-1 -ascorbate, gluconic acid, glycolic acid, green tea extract, 4-Hydroxy-5- methyl-3[2H]-furanone, 4-hydroxy
  • the additional skin lightening agent is selected from the group consisting of niacinamide, picolinamide, isonicotinamide, 12-hydroxystearic acid, 4-alkyl substituted resorcinol and mixtures thereof. More preferably, the additional skin lightening agent selected is 4-alkyl substituted resorcinol selected from the group consisting of 4-ethyl resorcinol (4-ER), 4-isopropyl resorcinol (4-IPR), 4-butyl resorcinol (4-BR), 4-pentyl resorcinol(4-PR), 4-phenylethyl resorcinol (4-PER), 4-HR and mixtures thereof. Even more preferably, the additional skin lightening agent is selected from the group consisting of 4-ER, 4-HR and mixtures thereof. Further more preferably, the additional skin lighting agent selected is 4-HR.
  • composition may comprise a combination of 6-MP along with one or more additional skin lightening agents described above.
  • the composition may preferably comprise 6-MP along with niacinamide, 6-MP along with 4- HR and 6-MP along with 4-HR and niacinamide.
  • the composition may preferably comprise 6-MP along with niacinamide and 4-HR.
  • the composition comprises from 0.001 to 10 wt%, more preferably from 0.01 to 8 wt%, even more preferably from 0.1 to 7 wt%, further more preferably from 0.1 to 5 wt%, still more preferably from 0.1 to 3 wt%, yet more preferably from 0.1 to 1 wt% and still further more preferably from 0.25 to 0.5 wt% of an additional skin lightening agent.
  • none of the additional skin lightening agents e.g. 4-alkyl substituted resorcinol, are encapsulated.
  • at least 20%, more preferably at least 30% and even more preferably at least 40%, further more preferably at least 50%, still more preferably at least 70%, even more preferably at least 90% and most preferably 100% of 4-alkyl substituted resorcinol is not encapsulated.
  • the composition comprises: a. 0.001 to 10 wt% 6-methyl picolinamide; and b. 0.001 to 5 wt% 4-alkyl substituted resorcinol.
  • the composition comprises: a. 0.001 to 10 wt% 6-methyl picolinamide; and b. 0.001 to 5 wt% 4-hexyl resorcinol.
  • UVA organic sunscreen
  • the composition comprises UVA organic sunscreen that absorbs UVA radiations and prevent them from reaching a surface e.g. skin of a user.
  • sunscreens that may be used as UVA organic sunscreen in the composition are dibenzoylmethane compound, bisdisulizole disodium (commercially available as Neo Heliopan® AP), diethylamino hydroxy benzoyl hexyl benzoate (commercially available as Uvinul® A Plus), Ecamsule (commercially available as Mexoryl SX) and Methyl anthranilate.
  • sunscreen that may be used as UVA organic sunscreen is selected from a dibenzoylmethane compound.
  • examples of sunscreen of dibenzoymethane compound that may be used as UVA organic sunscreen in the composition include BMDM (commercially available as Parsol® 1789 or Avobenzone), 2-methyldibenzoylmethane, 4-isopropyldibenzoyl- methane, 4-tert-butyldibenzoylmethane, 2,4-dimethyldibenzoylmethane, 2,5- dimethyldibenzoylmethane, 4,4'-diisopropyl-dibenzoylmethane, 2-methyl-5-isopropyl-4'- methoxydibenzoylmethane, 2-methyl-5-tert-butyl-4'-methoxy-dibenzoyl methane, 2,4- dimethyl-4'-methoxy dibenzoylmethane or 2,6-dimethyl-4-tert-
  • the composition comprises from 0.01 to 10 wt%, more preferably from 0.1 to 8 wt%, even more preferably from 1 to 6 wt%, further more preferably 1 to 5 wt%, still more preferably from 1 to 3 wt%, yet more preferably from 1 to 2.5 wt% of one or more UVA organic sunscreens.
  • the composition further comprises UV-B organic sunscreen.
  • the composition further comprises UVB organic sunscreens that absorbs UVB radiations and prevent them from reaching a surface e.g. skin of a user.
  • UVB organic sunscreens examples include compounds from the class of cinnamic acid, salicylic acid, diphenyl acrylic acid and derivatives thereof.
  • examples of such compounds include 2-ethylhexyl salicylate (commercially available as OctisalateTM), 3,3,5-Trimethylcyclohexyl 2- hydroxybenzoate (commercially available as HomosalateTM), Ethylhexyl Methoxycinnamate (commercially available as NeoHelipan® AV), 2-ethylhexyl 2-cyano- 3,3-diphenylacrylate (OCR; commercially available as OctocryleneTM), 2-Hydroxy-4- methoxybenzophenone (commercially available as OxybenzoneTM), 2-ethyl-hexyl-4- methoxy cinnamate (MCX; commercially available as Parsol MCXTM) and mixtures thereof.
  • UVB organic sunscreens that may be used in the composition are selected from OCR,
  • UVB organic sunscreens may preferably be incorporated from 0.1 to 10 wt%, more preferably from 0.5 to 7 wt%, even more preferably from 1 to 5 wt%, further more preferably from 1 to 3.5 wt%, yet more preferably from 1 to 3 wt%, still more preferably 1 to 2.5 wt% in the composition.
  • the composition comprises from 0.01 to 10 wt%, more preferably from 0.1 to 8 wt%, even more preferably from 1 to 6 wt%, further more preferably 1 to 5 wt%, still more preferably from 1 to 3 wt%, yet more preferably from 1 to 2.5 wt% of one or more UV-B organic sunscreens.
  • the composition further comprises inorganic sunblocks.
  • inorganic sunblocks examples include zinc oxide (ZnO), iron oxide, silica, such as fumed silica and titanium dioxide ( PO2).
  • ZnO zinc oxide
  • iron oxide iron oxide
  • silica such as fumed silica
  • titanium dioxide PO2
  • inorganic sunblock that may be used in the composition are selected from TiC>2 , ZnO and mixtures thereof.
  • inorganic sunblock may preferably be incorporated from 0.1 to 10 wt%, more preferably from 0.5 to 7 wt%, even more preferably from 1 to 5 wt%, further more preferably from 1 to 3.5 wt%, yet more preferably from 1 to 3 wt%, still more preferably 1 to 2.5 wt%, in the composition.
  • the composition further comprises a nonionic surfactant.
  • a nonionic surfactant is selected from those having HLB value in the range 9 to 20, preferably 10 to 19, more preferably 12 to 18, even more preferably 13 to 17 and yet more preferably 15 to 17.
  • HLB 20 x Mh / M wherein Mh is the molecular mass of the hydrophilic portion of the molecule and M is the molecular mass of the whole molecule, giving a result on an arbitrary scale of 0 to 20.
  • Typical values for various surfactants are given below:
  • a value >10 Water soluble A value from 4 to 8 indicates an anti-foaming agent
  • a value from 7 to 11 indicates a W/O (water in oil) emulsifier
  • a value from 12 to 16 indicates oil in water emulsifier
  • a value from 11 to 14 indicates a wetting agent
  • a value from 12 to 15 is typical of detergents
  • a value of 16 to 20 indicates a solubiliser or a hydrotrope.
  • the nonionic surfactant having HLB value in the range 9 to 20 is selected from fatty alcohol ethoxylates, alkyl phenol ethoxylates, polyoxyethylene sorbitan alkyl esters and mixtures thereof.
  • the nonionic surfactants are ones with at least 9 alkylene oxide groups preferably at least 9 ethylene oxide groups.
  • the nonionic surfactant having HLB value in the range 9 to 20 that may be present in the composition is fatty alcohol ethoxylate with saturated carbon chain having HLB higher than 15.5.
  • the composition comprises 0.5 to 5 wt%, more preferably 1 to 4 wt%, even more preferably from 2 to 3 wt% nonionic surfactant having HLB in the range 9 to 20.
  • the composition comprises fatty acid.
  • Fatty acids when present in a composition along with a soap provides the so-called vanishing cream effect, i.e. a composition, when applied on to the human skin, vanishes on the skin leaving behind no significant streaks of the composition.
  • the composition comprises fatty acids having 10 to 30, more preferably 12 to 25, even more preferably 14 to 20, further more preferably 16 to 18 carbon atoms.
  • fatty acids that may be used in the composition include pelargonic, lauric, myristic, palmitic, stearic, isostearic, oleic, linoleic, arachidic, behenic, erucic acid and mixtures thereof.
  • the fatty acid that may be used is stearic acid or palmitic acid or a mixture thereof.
  • the fatty acid in the present invention is preferably hystric acid which is substantially (generally about 90 to 95%) a mixture of stearic acid and palmitic acid in a ratio of between 55:45 to 45:55.
  • the composition comprises from 3 to 25 wt%, more preferably from 4 to 22 wt%, even more preferably from 6 to 20 wt%, further more preferably from 8 to 19 wt% and still more preferably from 10 to 18 wt% and yet more preferably from 12 to 16 wt% fatty acid. Soap
  • the composition comprises soap.
  • soap when present in combination with fatty acid in the composition, provides the vanishing effect described above.
  • soap of the invention is generally prepared by in-situ neutralization of fatty acid that may be present in the composition.
  • the soap has a carbon chain length that corresponds to the chain length of fatty acid in the composition.
  • the soap is formed from the fatty acid through use of alkali metal hydroxides e.g. sodium hydroxide or potassium hydroxide. Of the two, potassium hydroxide is more preferred.
  • the soap is preferably a potassium soap (potassium salt of fatty acid).
  • the composition comprises from 0.1 to 10 wt%, more preferably from 1 to 8 wt%, even more preferably from 2 to 7 wt%, further more preferably from 3 to 6 wt% soap.
  • the composition comprises water in amount from 5 to 99.9 wt%, more preferably from 10 to 95 wt%, even more preferably from 15 to 90 wt%, further more preferably from 20 to 80 wt%, still more preferably 25 to 75 wt% and yet more preferably 30 to 70 wt%.
  • the composition further comprises a polymer.
  • the polymer acts as thickener in the composition and improves sensorial properties of the composition.
  • the polymer is preferably selected from the following classes: acrylate / R-methacrylate copolymer e.g. acrylates/ steareth-20 methacrylate copolymer (commercially available as AculynTM 22) and acrylates/ beheneth-25 methacrylate copolymer (commercially available as AculynTM 28), acrylate / R-methacrylate crosspolymer e.g. acrylates/steareth-20 methacrylate crosspolymer (commercially available as AculynTM 88), acrylates copolymer (commercially available as AculynTM 33), acrylate/R-alkyl acrylate crosspolymer e.g.
  • acrylate / R-methacrylate copolymer e.g. acrylates/ steareth-20 methacrylate copolymer (commercially available as AculynTM 22) and acrylates/ beheneth-25 methacrylate copolymer (commercially available as
  • acrylates/C 10-C30 alkyl acrylate crosspolymer (commercially available as PemulenTM TR-2), copolymer of ammonium acryloyldimethyltaurate with vinyl pyrrolidone (commercially available as Aristoflex ® AVC), - copolymer of sodium acryloyldimethyltaurate with vinyl pyrrolidone
  • Aristoflex ® AVS crosspolymer of acryloyldimethyltaurate with R-alkyl acrylate and methyacrylate e.g. Ammonium acryloyldimethyltaurate/ beheneth-25 methacrylate crosspolymer (commercially available as Aristoflex ® HMB and Aristoflex ® BLV).
  • the composition comprises 0.1 to 5 wt%, more preferably 0.5 to 4.5 wt%, even more preferably 1 to 4 wt%, further more preferably from 1.5 to 3.5 wt%, still more preferably from 2 to 3 wt% polymer.
  • Emollients are preferably 0.1 to 5 wt%, more preferably 0.5 to 4.5 wt%, even more preferably 1 to 4 wt%, further more preferably from 1.5 to 3.5 wt%, still more preferably from 2 to 3 wt% polymer.
  • the composition further comprises emollients.
  • emollients that may be used in the composition include stearyl alcohol, glyceryl monoricinoleate, mink oil, cetyl alcohol, isopropyl isostearate, isobutyl palmitate, isocetyl stearate, oleyl alcohol, isopropyl laurate, hexyl laurate, decyl oleate, octadecan-2-ol, isocetyl alcohol, eicosanyl alcohol, behenyl alcohol, cetyl palmitate, silicone oils such as dimethylpolysiloxane, din-butyl sebacate, isopropyl myristate, isopropyl palmitate, isopropyl stearate, butyl stearate, polyethylene glycol, triethylene glycol, lanolin, cocoa butter, corn oil, cotton seed oil, olive oil, palm kernel oil, rape seed oil,
  • the composition further comprises solvents.
  • solvents that may be used in the composition include ethyl alcohol, isopropanol, acetone, ethylene glycol monoethyl ether, diethylene glycol monobutyl ether, diethylene glycol monoethyl ether and mixtures thereof. Powders
  • the composition further comprises powders.
  • powders that may be used in the composition include chalk, talc, fullers earth, kaolin, starch, gums, colloidal silica sodium polyacrylate, tetra alkyl and/or trialkyl aryl ammonium smectites, chemically modified magnesium aluminium silicate, organically modified montmorillonite clay, hydrated aluminium silicate, fumed silica, carboxyvinyl polymer, sodium carboxymethyl cellulose, ethylene glycol monostearate and mixtures thereof.
  • powders that may be used in the composition include chalk, talc, fullers earth, kaolin, starch, gums, colloidal silica sodium polyacrylate, tetra alkyl and/or trialkyl aryl ammonium smectites, chemically modified magnesium aluminium silicate, organically modified montmorillonite clay, hydrated aluminium silicate, fumed silica, carboxyvinyl polymer, sodium carboxymethyl cellulose, ethylene glycol
  • the composition further comprises preservatives to protect against the growth of potentially harmful microorganisms.
  • preservatives examples include alkyl esters of para-hydroxybenzoic acid, hydantoin derivatives, propionate salts, and a variety of quaternary ammonium compounds.
  • ingredients that may be used as preservative in the composition are sodium benzoate, iodopropynyl butyl carbamate, methylisothiazolinone, iodopropynylbutylcarbamate, phenoxyethanol, methyl paraben, propyl paraben, imidazolidinyl urea, sodium dehydroacetate, ethylhexylglycerin, benzyl alcohol, alkane diols and mixtures thereof.
  • the alkane diols that are suitable for use as preservative are C6-C12 alkanes that are vicinally substituted with hydroxy groups.
  • Illustrative examples include 1,2-octane diol (caprylyl glycol), 2,3-octane diol, 1,2-nonane diol, 1,2-decane diol, 1,2-hexane diol, 3,4-octane diol, mixtures thereof or the like where caprylyl glycol is typically the most preferred.
  • preservatives are added preferably in an amount 0.001 to 5 wt%, more preferably 0.01 to 3 wt% and most preferably 0.02 to 2 wt%.
  • the composition further comprises a range of other optional ingredients that include antioxidants, binders, buffering agents, colorants, astringents, fragrance, opacifying agents, conditioners, exfoliating agents, pH adjusters, skin sensates, skin soothing agents, and skin healing agents.
  • antioxidants binders, buffering agents, colorants, astringents, fragrance, opacifying agents, conditioners, exfoliating agents, pH adjusters, skin sensates, skin soothing agents, and skin healing agents.
  • the composition is preferably formulated in the form of a powder, flake, lotion, cream, gel or mousse. More preferably, the composition is formulated in the form of cream or lotion and most preferably in the form of cream.
  • the composition can be a leave-on or wash-off type of composition.
  • the composition is preferably a leave-on type of composition.
  • the packaging for the composition of this invention can be a patch, bottle, tube, roll-ball applicator, propellant driven aerosol device, squeeze container or lidded jar.
  • the composition can be packaged in a suitable container to suit its viscosity and intended use by the consumer.
  • a lotion or fluid cream can be packaged in a bottle or a roll-ball applicator or a propellant-driven aerosol device or a container fitted with a pump suitable for finger operation.
  • a cream it can simply be stored in a non-deformable bottle or squeeze container, such as a tube or a lidded jar.
  • a solid or semi-solid stick it may be packaged in a suitable container for manually or mechanically pushing out or extruding the composition.
  • composition is non-therapeutic.
  • the present invention relates to a method for providing even tone to skin wherein the method comprises:
  • the method is intended primarily for using the cosmetic composition for topical application to human skin to lighten the skin, to reduce the degree of pigmentation in the skin, or to even the skin tone.
  • the method is non-therapeutic.
  • an appropriate quantity for example from 1 to 5 ml_, may be applied to exposed areas of the skin, from a suitable container or applicator and, if necessary, it is then spread over and/or rubbed into the skin using the hand or fingers or a suitable device.
  • the composition may be removed by rinsing it preferably with water. If the step of rinsing is carried out, it is preferably carried out after 30 minutes, more preferably after 20 minutes, even more preferably after 10 minutes and further more preferably after 5 minutes from when it was applied on to the skin in the first step.
  • the present invention relates to the use of the composition of the first aspect for providing even tone to skin.
  • the composition of the first aspect was applied to the skin, more even skin tone was obtained.
  • the use Is non- therapeutic.
  • the present invention also relates to use of 6-MP for providing even skin tone. It has been found that when 6-MP was applied on to the skin, more even skin tone was obtained. Preferably, the use is non-therapeutic.
  • non-therapeutic as referred to in the first, the second, the third and the fourth aspect, means a cosmetic improvement in skin appearance in healthy subjects, rather than treating any underlying medical disease or disorder.
  • HPE Reconstructed human pigmented epidermis
  • Episkin France, age - 10 days, 0.5 cm 2 , Phototype VI
  • Human epidermal melanocytes neonatal, darkly pigmented donor, (HEMn-DP; C-202- 5C, Invitrogen)
  • HMGS Human melanocyte growth supplement
  • HaCaT cell line was provided by Professor N. E. Fusenig (German Cancer Research Center, Heidelberg, Germany), Dulbecco's Modified Eagle Medium (DMEM; AL219A-500ML, HIMEDIA), Fetal Bovine Serum (FBS; 16000044-500 ML, Invitrogen),
  • Episkin RHPE inserts were removed from the transport plate and placed in to a new 24 well plate containing 500 pL of maintenance media (provided by supplier). Inserts were placed gently to avoid any air bubble between an insert and the media.
  • Episkin RHPE inserts were removed from the plate, the spent media was collected and stored in -80°C.
  • Inserts were transferred to a fresh 24 well plate containing 450 pL of growth media and incubated at 37°C under 5% CO2.
  • Episkin RHPE were treated with 10 pl_ of neat lysis reagent (10X) supplied in the LDH kit, for 6 to 8 h. After the treatment, the spent media was collected and stored in -80°C. Ultrapure water wash was given to remove the formulation sticking to the Episkin RHPE tissue. The Episkin RHPE inserts were progressed for further analysis.
  • reaction mixture 50 pL was added to each well and were mixed by gentle tapping.
  • L* lightness
  • CM26000d An instrumental measurement of lightness (L*) was carried out on an intact RHPE post treatment, using a CM26000d.
  • the chromameter works on the principle of reflection and absorption of specific wavelengths of light in the L*a*b* colour space, in this colour space L* indicates lightness and a* and b* are chromaticity co-ordinates, a* is the red to green direction and b* is the yellow to blue direction.
  • the main parameter of interest was pigmentation reduction therefore the lightness, (L*) score were recorded. All readings were taken from the underside of the cultures and in triplicate to account for any variations in the readings. The mean and standard deviations for each triplicate were calculated for each treatment and compared against the scores for the untreated controls.
  • Episkin RHPE cultures were removed from the incubation plates and melanin content was estimated as described below.
  • Episkin RHPE tissues were carefully removed from the insert and placed in 1.5 ml_ tubes tissues.
  • Tubes were centrifuged at 1000 rpm for 10 minutes.
  • Melanin synthesis/content assay The principle behind this assay is to quantify the amount of change in melanin in melanocytes over a period of 72 hours to mimic process of melanin synthesis in skin, a first key step in regulating skin colour.
  • primary melanocytes isolated from various donors (ethnic, phototype) were cultured as monolayers. They were then treated with different regulators expected to alter the production of melanin. After 72 hours, cells were lysed and change in melanin was measured by standard spectrophotometric method. We evaluated this method with known melanin production inhibitors and showed the specificity and robustness of this method.
  • Human primary melanocytes were grown in melanocytes growth medium (MGM) with human melanocyte growth supplement. 500 pL/well (5X10 4 cells/well) of this solution was plated in a 24 wells plate and incubated in an incubator (Thermo Scientific, Model 3111) at 37°C with 5% CO2 atmosphere. After 24 hours of incubation, cell cultures were treated with the lead actives either dissolved in water or DMSO. The cells were again incubated for 72 hours in an incubator (Thermo Scientific, Model 3111; conditions: 5% CO2, at 37°C). After incubation, spent media is drained and fresh solution of 0.15 ml of 1N NaOH (in 10% DMSO) per well was added.
  • MGM melanocytes growth medium

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne une composition cosmétique. En particulier, la présente invention concerne une composition cosmétique comprenant du 6-méthyl picolinamide qui confère un teint régulier à la peau.
PCT/EP2021/063837 2020-06-10 2021-05-25 Composition cosmétique comprenant du 6-méthyl-picolinamide WO2021249760A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20179309 2020-06-10
EP20179309.8 2020-06-10

Publications (1)

Publication Number Publication Date
WO2021249760A1 true WO2021249760A1 (fr) 2021-12-16

Family

ID=71092283

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2021/063837 WO2021249760A1 (fr) 2020-06-10 2021-05-25 Composition cosmétique comprenant du 6-méthyl-picolinamide

Country Status (1)

Country Link
WO (1) WO2021249760A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411741A (en) * 1993-07-29 1995-05-02 Zaias; Nardo Method and composition for skin depigmentation
WO2013030794A2 (fr) 2011-08-31 2013-03-07 Behrooz Kasraee Utilisation de pyridines substituées en tant que composés de dépigmentation de la peau
WO2017060211A1 (fr) * 2015-10-05 2017-04-13 Unilever N.V. Composition d'éclaircissement de la peau
WO2017215863A1 (fr) 2016-06-15 2017-12-21 Unilever N.V. Procédé et composition cosmétique pour une meilleure administration transdermique de résorcinol substitué par un alkyle
WO2019029922A1 (fr) * 2017-08-07 2019-02-14 Unilever N.V. Composition de soins personnels

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411741A (en) * 1993-07-29 1995-05-02 Zaias; Nardo Method and composition for skin depigmentation
WO2013030794A2 (fr) 2011-08-31 2013-03-07 Behrooz Kasraee Utilisation de pyridines substituées en tant que composés de dépigmentation de la peau
WO2017060211A1 (fr) * 2015-10-05 2017-04-13 Unilever N.V. Composition d'éclaircissement de la peau
WO2017215863A1 (fr) 2016-06-15 2017-12-21 Unilever N.V. Procédé et composition cosmétique pour une meilleure administration transdermique de résorcinol substitué par un alkyle
WO2019029922A1 (fr) * 2017-08-07 2019-02-14 Unilever N.V. Composition de soins personnels

Similar Documents

Publication Publication Date Title
US20210106509A1 (en) A sunscreen composition
JP7116683B2 (ja) 皮膚を明るくし、日光からの保護をもたらし、ビタミンｄ産生を可能にする組成物
ES2611791T3 (es) Composiciones para aclarar el color de la piel
US20090130035A1 (en) Stabilized preparations comprising phenolic compounds and benzophenones
BRPI0721862B1 (pt) preparação compreendendo sais solúveis estáveis de ácido fenilbenzimidazol sulfônico, e uso de aminoácidos básicos
US20100034763A1 (en) Skin Lightening Composition Comprising CO2 Extracts
KR20160123753A (ko) 피부미백용 조성물
EP3664775B1 (fr) Composition de soins personnels pour eclaircire la peau
US20210299034A1 (en) A Topical Composition
EP3509566B1 (fr) Composés pour la reduction du contenu cellulaire de melanin
WO2021249760A1 (fr) Composition cosmétique comprenant du 6-méthyl-picolinamide
KR20190023651A (ko) 피부미백용 조성물
WO2021234005A1 (fr) Composition de soins personnels
US11419803B2 (en) Skin darkening composition
EP3784355A1 (fr) Composition d'écran solaire
WO2024099715A1 (fr) Composition éclaircissant la peau
CA3232323A1 (fr) Composition de soins personnels comprenant de la vitamine k2 et de l'acide hydroxystearique
KR20200031760A (ko) 피부미백용 조성물
JP2024501435A (ja) 皮膚の化粧的処置のためのエストリドエステル
EA043647B1 (ru) Способ потемнения кожи
EA042490B1 (ru) Композиция для осветления кожи

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21726681

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21726681

Country of ref document: EP

Kind code of ref document: A1